Press Releases

Lodo Therapeutics Corp. (Lodo), a biotechnology company reinventing natural product drug discovery by applying its informatics-enabled technology platform to previously undruggable disease targets, today announced that it has completed the acquisition of Conifer Point Pharmaceuticals, LLC (Conifer Point). Conifer Point has proprietary tools and deep expertise in computational structural biology and cheminformatics. Lodo will integrate Conifer Point's technology and know-how to enhance its

Biogen Inc. and Denali Therapeutics Inc. announced that they have signed a binding agreement to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease. Biogen will also receive rights to opt into two programs and a right of first negotiation for two additional programs, in each case for neurodegenerative diseases leveraging Denali’s Transport Vehicle (TV) technology platform to cross the blood-b

 A biopharmaceutical company repurposing nafamostat, a generic remedy for pancreatitis and acute kidney injury, is one step closer to a treatment in its fight against COVID-19. Covistat, an Ensysce Biosciences subsidiary, announced its acquisition of Mucokinetica's technology and intellectual property, which will accelerate efforts to develop a low-cost treatment that helps the body's ability to block the coronavirus—and its mutating variations—from infiltrating our c

Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced it has entered into an Option Agreement with Torii Pharmaceutical Co., Ltd. (Torii) granting Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102. “We are extremely

Axsome Therapeutics, Inc. a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,  announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for AXS-12 for the treatment of cataplexy in patients with narcolepsy. AXS-12 is a novel, oral, highly selective and potent norepinephrine reuptake inhibitor. Axsome previously received Orphan Drug Designation from the FDA for AXS-12 for t

ANA Therapeutics (ANA), a Silicon Valley-based biotech start-up announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ANA001 (niclosamide capsules) as a potential treatment for COVID-19, making it the first U.S.-based company to conduct a human clinical trial to determine the efficacy of niclosamide to treat COVID-19. ANA Therapeutics clinical trial will seek to enroll at least 400 patients with COVID-19 at 10

BryoLogyx, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia (ALL) and lymphoma. The study, expected to start later this year, will be the first in patients to evaluate the ability of bryostatin-1 to upregulate expression of CD22, a can

Metabolon, Inc., a global leader in metabolomics, has started a multi-year collaboration with Merck KGaA, Darmstadt, Germany, a leading company in the field of science and technology . Merck KGaA, Darmstadt, Germany carries out biopharmaceutical activities in the USA and Canada under the name EMD Serono. As an exploratory metabolomics partner, Metabolon will support clinical and translational research projects in the various therapeutic areas. The agreement will be effective from Au

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced that the Investigational New Drug (IND) application submitted by its partner, Personalized Stem Cells, Inc. (PSC), has received FDA approval for the treatment of COVID-19 and pneumonia patients using stem cell therapy. Calidi has partnered with PSC for over two years—most recently contributing the stem cell lines used to manufacture treatment

Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., announced that it received FDA Emergency Use Authorization (EUA) and is scaling up capacity for CRL Rapid Response™, a saliva-based COVID-19 RT-PCR test that can be self-collected at home, work or any other setting. The test, shown in CRL's EUA studies to be more sensitive and accurate than the standard COVID-19 anterior nasal swab test, detects the presence of coronavir